PMID- 36855913
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 1868-1891 (Electronic)
IS  - 1868-1883 (Linking)
VI  - 44
IP  - 3
DP  - 2023 Sep 1
TI  - Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients 
      with type 2 diabetic nephropathy.
PG  - 243-249
LID - 10.1515/hmbci-2022-0056 [doi]
AB  - OBJECTIVES: Type 2 diabetic Mellitus (T2DM) is the most common systemic and 
      endocrine disease in humans, and diabetic nephropathy is one of the most serious 
      complications of this disorder. The polymorphisms in the apolipoprotein A5 
      (ApoA5) gene are strongly related to hypertriglyceridemia and are considered a 
      predisposing factor for diabetic nephropathy. The current study proposed to 
      examine the association of APOA5-S19W polymorphism with serum lipids levels in 
      patients with type 2 diabetic nephropathy in Mazandaran province. METHODS: This 
      case-control study was designed to determine the association of APOA5-S19W 
      polymorphism with plasma lipid profile in 161 T2DM patients with nephropathy 
      (DN+), without nephropathy (DN-), and in 58 healthy individuals. Lipid profile 
      values were measured using Pars Azmoun commercial kits. S19W variant, one of the 
      polymorphisms of the APOA5 gene, was determined by PCR-restriction fragment 
      length polymorphism (PCR-RFLP) and Taq1 restriction enzyme. RESULTS: In 
      comparison between the three groups, DN+ had a higher mean TG than DN- and the 
      control group (p<0.001). The incidence of the G allele in DN+ was not significant 
      compared to groups of DN-. Comparing the relationship between the mean of 
      biochemical variables with CC and CG genotypes showed that the mean level of TG 
      in people with CC genotype was increased compared to people with CG genotype in 
      diabetic patients. However, this increase was not significant (p=0.19). 
      CONCLUSIONS: There was no association between SNP APOA5 S19W and serum lipids in 
      diabetic patients with and without nephropathy.
CI  - (c) 2023 Walter de Gruyter GmbH, Berlin/Boston.
FAU - Mirabedini, Shivasadat
AU  - Mirabedini S
AD  - Department of Clinical Biochemistry and Medical Genetics, Molecular and Cell 
      Biology Research Center, Faculty of Medicine, Mazandaran University of Medical 
      Sciences, Sari, Iran.
FAU - Musavi, Hadis
AU  - Musavi H
AD  - Department of Clinical Biochemistry, School of Medicine, Babol University of 
      Medical Sciences, Babol, Iran.
FAU - Makhlough, Atieh
AU  - Makhlough A
AD  - Department of Internal Medicine, Diabetes Research Center, Sari Imam Khomeini 
      Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
FAU - Hashemi-Sooteh, Mohammad-Bagher
AU  - Hashemi-Sooteh MB
AD  - Department of Clinical Biochemistry and Medical Genetics, Molecular and Cell 
      Biology Research Center, Faculty of Medicine, Mazandaran University of Medical 
      Sciences, Sari, Iran.
FAU - Zargari, Mehryar
AU  - Zargari M
AUID- ORCID: 0000-0002-5994-786X
AD  - Department of Clinical Biochemistry and Medical Genetics, Molecular and Cell 
      Biology Research Center, Faculty of Medicine, Mazandaran University of Medical 
      Sciences, Sari, Iran.
LA  - eng
PT  - Journal Article
DEP - 20230302
PL  - Germany
TA  - Horm Mol Biol Clin Investig
JT  - Hormone molecular biology and clinical investigation
JID - 101538885
RN  - 0 (Apolipoproteins A)
RN  - 0 (Apolipoprotein A-V)
RN  - 0 (APOA5 protein, human)
SB  - IM
MH  - Humans
MH  - *Diabetic Nephropathies/genetics
MH  - Apolipoproteins A/genetics
MH  - Apolipoprotein A-V/genetics
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/complications/genetics
MH  - Genetic Predisposition to Disease
OTO - NOTNLM
OT  - apolipoprotein A5
OT  - lipid profile
OT  - polymorphism
OT  - type 2 diabetic nephropathy
EDAT- 2023/03/02 06:00
MHDA- 2023/10/23 12:44
CRDT- 2023/03/01 03:34
PHST- 2022/06/02 00:00 [received]
PHST- 2023/02/11 00:00 [accepted]
PHST- 2023/10/23 12:44 [medline]
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/01 03:34 [entrez]
AID - hmbci-2022-0056 [pii]
AID - 10.1515/hmbci-2022-0056 [doi]
PST - epublish
SO  - Horm Mol Biol Clin Investig. 2023 Mar 2;44(3):243-249. doi: 
      10.1515/hmbci-2022-0056. eCollection 2023 Sep 1.